Perceptive Advisors LLC Has $46.95 Million Position in Neurocrine Biosciences, Inc. $NBIX

Perceptive Advisors LLC lessened its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 26.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 331,050 shares of the company’s stock after selling 119,000 shares during the period. Perceptive Advisors LLC’s holdings in Neurocrine Biosciences were worth $46,953,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Huntington National Bank boosted its stake in shares of Neurocrine Biosciences by 12.6% in the 4th quarter. Huntington National Bank now owns 678 shares of the company’s stock valued at $96,000 after purchasing an additional 76 shares in the last quarter. Perigon Wealth Management LLC boosted its stake in shares of Neurocrine Biosciences by 3.1% in the 4th quarter. Perigon Wealth Management LLC now owns 2,590 shares of the company’s stock valued at $367,000 after purchasing an additional 78 shares in the last quarter. Motley Fool Asset Management LLC boosted its stake in shares of Neurocrine Biosciences by 4.8% in the 4th quarter. Motley Fool Asset Management LLC now owns 1,693 shares of the company’s stock valued at $240,000 after purchasing an additional 78 shares in the last quarter. Main Management ETF Advisors LLC boosted its stake in shares of Neurocrine Biosciences by 1.0% in the 4th quarter. Main Management ETF Advisors LLC now owns 7,830 shares of the company’s stock valued at $1,111,000 after purchasing an additional 80 shares in the last quarter. Finally, Signaturefd LLC boosted its stake in shares of Neurocrine Biosciences by 4.5% in the 4th quarter. Signaturefd LLC now owns 1,925 shares of the company’s stock valued at $273,000 after purchasing an additional 83 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on NBIX shares. Leerink Partners boosted their target price on shares of Neurocrine Biosciences from $160.00 to $170.00 and gave the company an “outperform” rating in a research note on Wednesday, April 22nd. HC Wainwright boosted their target price on shares of Neurocrine Biosciences from $192.00 to $215.00 and gave the company a “buy” rating in a research note on Tuesday, April 7th. Zacks Research upgraded shares of Neurocrine Biosciences from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 15th. Wolfe Research started coverage on shares of Neurocrine Biosciences in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $160.00 target price on the stock. Finally, Piper Sandler boosted their target price on shares of Neurocrine Biosciences from $190.00 to $207.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $187.52.

Insiders Place Their Bets

In related news, insider Jude Onyia sold 11,000 shares of Neurocrine Biosciences stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $160.25, for a total value of $1,762,750.00. Following the completion of the transaction, the insider directly owned 25,846 shares of the company’s stock, valued at $4,141,821.50. The trade was a 29.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephen A. Sherwin sold 25,000 shares of the business’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $165.32, for a total value of $4,133,000.00. Following the sale, the director directly owned 15,860 shares of the company’s stock, valued at $2,621,975.20. This represents a 61.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 355,234 shares of company stock valued at $55,330,060 over the last three months. Company insiders own 4.60% of the company’s stock.

Neurocrine Biosciences Stock Up 1.6%

Neurocrine Biosciences stock opened at $159.00 on Thursday. The stock has a 50-day simple moving average of $147.48 and a 200 day simple moving average of $140.68. Neurocrine Biosciences, Inc. has a 12-month low of $122.14 and a 12-month high of $169.57. The stock has a market capitalization of $15.99 billion, a price-to-earnings ratio of 24.50, a P/E/G ratio of 1.17 and a beta of 0.40.

Neurocrine Biosciences Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.